Shayla Hesse

Shayla Hesse

Auto-generated profile, based on publicly available information

Shayla Hesse

Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
GSGina Suh
Gina Suh
TLthomas patrick lodise
thomas patrick lodise
PTPranita D. Tamma
Pranita D. Tamma
JKJane M. Knisely
Jane M. Knisely
JAJose Alexander
Jose Alexander
FGfor the Antibacterial Resistance Leadership Group
for the Antibacterial Resistance Leadership Group
Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases have risen exponentially but have varied widely in approach, methodology, clinical situations in which phage therapy might be considered, dosing, route of administration, and outcomes.

25 February 2020 in mBio
Verified
Journal Article
Open access
PDF file
SHShayla Hesse
Shayla Hesse
MRManoj Rajaure
Manoj Rajaure
EWErin Wall
Erin Wall
JJJoy Johnson
Joy Johnson
VBValery Bliskovsky
Valery Bliskovsky
SASankar Adhya
Sankar Adhya
The therapeutic use of bacteriophage (phage) is garnering renewed interest in the setting of difficult-to-treat infections. Phage resistance is one major limitation of phage therapy; therefore, developing effective strategies to avert or lessen its impact is critical. Characterization of in vitro phage resistance may be an important first step in evaluating the relative likelihood with which phage-resistant populations emerge, the most likely phenotypes of resistant mutants, and the effect of certain phage cocktail combinations in increasing or decreasing the genetic barrier to resistance. If this information confers predictive power in vivo , then routine studies of phage-resistant mutants and their in vitro evolution should be a valuable means for improving the safety and efficacy of phage therapy in humans.

8 September 2019 in Annual Review of Microbiology
Verified
Journal Article
Closed access
SHShayla Hesse
Shayla Hesse
SASankar Adhya
Sankar Adhya
Burgeoning problems of antimicrobial resistance dictate that new solutions be developed to combat old foes. Use of lytic bacteriophages (phages) for the treatment of drug-resistant bacterial infections is one approach that has gained significant traction in recent years. Fueled by reports of experimental phage therapy cases with very positive patient outcomes, several early-stage clinical trials of therapeutic phage products have been launched in the United States. Eventual licensure enabling widespread access to phages is the goal; however, new paths to regulatory approval and mass-market distribution, distinct from those of small-molecule antibiotics, must be forged first. This review highlights unique aspects related to the clinical use of phages, including advantages to be reaped as well as challenges to be overcome.

23 February 2021 in mBio
Verified
Journal Article
Closed access
PDF file
SHShayla Hesse
Shayla Hesse
NMNatalia Malachowa
Natalia Malachowa
APAdeline R. Porter
Adeline R. Porter
BFBrett Freedman
Brett Freedman
SKScott D. Kobayashi
Scott D. Kobayashi
FDFrank R. DeLeo
Frank R. DeLeo
Infections caused by multidrug-resistant K. pneumoniae pose a serious threat to at-risk patients and present a therapeutic challenge for clinicians. Bacteriophage (phage) therapy is an alternative treatment approach that has been associated with positive clinical outcomes when administered experimentally to patients with refractory bacterial infections.

19 November 2008 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
Atique AhmedAtique Ahmed
Atique Ahmed
RSRebecca L. Schmidt
Rebecca L. Schmidt
CPCheol Hong Park
Cheol Hong Park
NRNanette R. Reed
Nanette R. Reed
SHShayla E. Hesse
Shayla E. Hesse
Amy TangAmy Tang
Amy Tang
Hyperactivated epidermal growth factor receptor (EGFR) and/or RAS signaling drives cellular transformation and tumorigenesis in human lung cancers, but agents that block activated EGFR and RAS signaling have not yet been demonstrated to substantially extend patients’ lives. The human homolog of Drosophila seven-in-absentia—SIAH-1 and SIAH-2—are ubiquitin E3 ligases and conserved downstream components of the RAS pathway that are required for mammalian RAS signal transduction. We examined whether inhibiting SIAH-2 function blocks lung cancer growth. The antiproliferative and antitumorigenic effects of lentiviral expression of anti-SIAH-2 molecules (ie, a dominant-negative protease-deficient mutant of SIAH-2 [SIAH-2 PD ] and short hairpin RNA [shRNA]–mediated gene knockdown against SIAH-2) were assayed in normal human lung epithelial BEAS-2B cells and in human lung cancer BZR, A549, H727, and UMC11 cells by measuring cell proliferation rates, by assessing MAPK and other activated downstream components of the RAS pathway by immunoblotting, assessing apoptosis by terminal deoxynucleotidyltransferase–mediated UTP end-labeling (TUNEL) assay, quantifying anchorage-independent cell growth in soft agar, and assessing A549 cell–derived tumor growth in athymic nude mice (groups of 10 mice, with two injections of 1 × 10 6 cells each at the dorsal left and right scapular areas). All statistical tests were two-sided. SIAH-2 deficiency in human lung cancer cell lines reduced MAPK signaling and statistically significantly inhibited cell proliferation compared with those in SIAH-proficient cells ( P < .001) and increased apoptosis (TUNEL-positive A549 cells 3 days after lentivirus infection: SIAH-2 PD vs control, 30.1% vs 0.0%, difference = 30.1%, 95% confidence interval [CI] = 23.1% to 37.0%, P < .001; SIAH-2-shRNA#6 vs control shRNA, 27.9% vs 0.0%, difference = 27.9%, 95% CI = 23.1% to 32.6%, P < .001). SIAH-2 deficiency also reduced anchorage-independent growth of A549 cells in soft agar (mean number of colonies: SIAH-2 PD vs control, 124.7 vs 57.3, difference = 67.3, 95% CI = 49.4 to 85.3, P < .001; shRNA-SIAH-2#6 vs shRNA control: 27.0 vs 119.7, difference = 92.7, 95% CI = 69.8 to 115.5, P < .001), and blocked the growth of A549 cell–derived tumors in nude mice (mean tumor volume on day 36 after A549 cell injection: SIAH-2 PD infected vs uninfected, 191.0 vs 558.5 mm 3 , difference = 367.5 mm 3 , 95% CI = 237.6 to 497.4 mm 3 , P < .001; SIAH-2 PD infected vs control infected, 191.0 vs 418.3 mm 3 , difference = 227.5 mm 3 , 95% CI = 87.4 to 367.1 mm 3 , P = .003; mean resected tumor weight: SIAH-2 PD infected vs uninfected, 0.12 vs 0.48 g, difference = 0.36 g, 95% CI = 0.23 to 0.50 g, P < .001; SIAH-2 PD infected vs control infected, 0.12 vs 0.29 g, difference = 0.17 g, 95% CI = 0.04 to 0.31 g, P = .016). SIAH-2 may be a viable target for novel anti-RAS and anticancer agents aimed at inhibiting EGFR and/or RAS-mediated tumorigenesis.

1 September 2017 in Medical Mycology Case Reports
Verified
Journal Article
Open access
SHShayla E. Hesse
Shayla E. Hesse
PLPaul M. Luethy
Paul M. Luethy
JBJohn H. Beigel
John H. Beigel
AZAdrian M. Zelazny
Adrian M. Zelazny
We present a case of an immunocompromised woman with fever, pulmonary infiltrates and multiple bronchoalveolar lavage (BAL) cultures positive for Penicillium citrinum with a concomitant high BAL galactomannan level. We report the results of Aspergillus galactomannan testing performed on culture supernatants from her P. citrinum strain that confirmed the suspected cross-reactivity. Finally, we discuss the clinical significance and antifungal susceptibility of P. citrinum in our case and review the literature.